Key result
Astragaloside IV boosts LVEF by ~17% vs control in rat models of heart failure.
Why the study?
Astragaloside IV has potential protective effects on cardiac function, but systematic evaluations of its use for treating heart failure were lacking.
Does Astragaloside IV improve cardiac function in rat models of heart failure?
Meta-Analysis (n=489)
Does Astragaloside IV improve cardiac function in rat models of heart failure?
Effect estimate: MD 17.04 (95% CI 11.01-23.08)
p-value: p=<0.01
In a meta-analysis of preclinical rat models, Astragaloside IV demonstrated a dose-dependent improvement in cardiac function and reduction in cardiac hypertrophy.
Should not change heart failure practice; leaves open human translation of rat-model LVEF gains.
Background: Astragaloside IV (ASIV) is the primary pharmacologically active compound found in Astragalus propinquus Schischkin, which has potential protective effects on cardiac function. However, there are almost no systematic evaluations of ASIV for the treatment of heart failure (HF). Methods: Preclinical studies published before 27 December 2022, were retrieved from PubMed, Web of Science, MEDLINE, SinoMed, Chinese National Knowledge Infrastructure (CNKI), VIP information database, and Wanfang Data information site. The quality of included research was evaluated using SYRCLE’s RoB tool. Review Manager 5.4.1 was used to perform meta-analyses of the cardiac function parameters and other indicators. Regression analysis was conducted to observe the dose-efficacy relationship. Results: Nineteen studies involving 489 animals were included. Results indicated that compared with the control group, ASIV could enhance cardiac function indicators, including left ventricular ejection fraction (LVEF), left ventricular fractional shortening (LVFS), left ventricular pressure change rate (±dp/dt max ), left ventricular end-diastolic pressure (LVEDP), left ventricular systolic pressure (LVSP), heart weight/body weight (HW/BW) and left ventricular weight/body weight (LVW/BW). Furthermore, the regression analysis showed that the treatment of HF with ASIV was dose-dependent. Conclusion: Findings suggest that ASIV can inhibit cardiac hypertrophy by reducing cardiac preload and afterload, thereby protecting cardiac function.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2023) conducted a meta-analysis in Heart failure (n=489). Astragaloside IV (ASIV) vs. Vehicle, saline, or no treatment was evaluated on Left ventricular ejection fraction (LVEF) (MD 17.04, 95% CI 11.01-23.08, p=<0.01). Astragaloside IV significantly improved left ventricular ejection fraction by a mean deviation of 17.04 compared to control in rat models of heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: